Sopharma AD-SofiaWAR:SPH 66 EV-to-FCF is -38.79 as of Jul. 03, 2026. GuruFocus rates WAR:SPH with a GF Score™ of 66/100 and a GF Value™ of zł13.51 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 75 Medical Distribution companies, Sopharma AD-Sofia ranks worse than 1333332% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Sopharma AD-Sofia's Enterprise Value is zł5,609 Mil.
Sopharma AD-Sofia's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was zł-145 Mil. Therefore, Sopharma AD-Sofia's EV-to-FCF for today is -38.79.
The historical rank and industry rank for Sopharma AD-Sofia's EV-to-FCF or its related term are showing as below:
WAR:SPH'
s EV-to-FCF Range Over the Past 10 Years
Min: -79.43 Med: -9.75 Max: 1341.88
Current: -39
During the past 13 years, the highest EV-to-FCF of Sopharma AD-Sofia was 1341.88. The lowest was -79.43. And the median was -9.75.
WAR:SPH's EV-to-FCF is ranked worse than 100% of 75
companies
in the Medical Distribution industry
Industry Median: 16.66
vs WAR:SPH: -39.00
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sopharma AD-Sofia's PE Ratio (TTM) for today is calculated as:
Sopharma AD-Sofia's share price for today is zł7.70.
Sopharma AD-Sofia's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł0.897.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Sopharma AD-Sofia EV-to-FCF Related Terms
Sopharma AD-Sofia EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Sopharma AD-Sofia's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Sopharma AD-Sofia's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sopharma AD-Sofia EV-to-FCF vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sopharma AD-Sofia's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Sopharma AD-Sofia's EV-to-FCF falls into.
Sopharma AD-Sofia's current Enterprise Value is zł5,609 Mil.
Sopharma AD-Sofia's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-145 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sopharma AD-Sofia (WAR:SPH) has a EV-to-FCF of -38.79 as of Jul. 03, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sopharma AD-Sofia and its competitors. According to the industry distribution chart, Sopharma AD-Sofia ranks #999999 out of 75 companies in the Medical Distribution industry.
Is Sopharma AD-Sofia's EV-to-FCF too high?
Sopharma AD-Sofia's current EV-to-FCF is -38.79. Based on the distribution chart, Sopharma AD-Sofia ranks #999999 out of 75 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Sopharma AD-Sofia has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sopharma AD-Sofia's EV-to-FCF compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Sopharma AD-Sofia ranks #999999 out of 75 companies for EV-to-FCF. This places Sopharma AD-Sofia in the lower half of its industry. The industry median EV-to-FCF is 16.66. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Distribution company?
The median EV-to-FCF among Medical Distribution companies is 16.66, based on 75 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sopharma AD-Sofia and its competitors. For the Medical Distribution industry, the median EV-to-FCF is 16.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sopharma AD-Sofia's current EV-to-FCF is -38.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma AD-Sofia stock overvalued right now?
Based on GuruFocus' analysis, Sopharma AD-Sofia (WAR:SPH) is currently considered Possible Value Trap. The stock's GF Value™ is zł13.51, compared to a current price of zł7.70 — trading 43% below its estimated fair value. The current EV-to-FCF is -38.79. Sopharma AD-Sofia's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Sopharma AD-Sofia (WAR:SPH), the current EV-to-FCF is -38.79 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sopharma AD-Sofia (WAR:SPH) Overvalued in 2026?
Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be undervalued.
The current stock price of zł7.70 is trading 43% below its estimated GF Value™ of zł13.51.
GuruFocus considers Sopharma AD-Sofia to be Possible Value Trap.
Key valuation signals for WAR:SPH:
EV-to-FCF: -38.79
GF Value™: zł13.51 vs. price of zł7.70 (43% below fair value)
No single metric tells the full story. See the WAR:SPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
66GF Score
Get the complete analysis for WAR:SPH
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SPH has been successfully added to your 
